$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000143774921026620 Filed on November 15, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$16.17M	$11.35M	$7.970M
YoY Change	102.94%	227.97%
Cost Of Revenue	$1.589M	$1.244M	$650.0K
YoY Change	144.46%	302.59%
Gross Profit	$14.59M	$10.11M	$7.310M
YoY Change	99.52%	220.65%
Gross Profit Margin	90.18%	89.04%	91.72%
Selling, General & Admin	$21.42M	$21.62M	$22.16M
YoY Change	-3.35%	-2.0%	12.2%
% of Gross Profit	146.85%	213.95%	303.15%
Research & Development	$13.08M	$11.92M	$12.41M
YoY Change	5.41%	16.77%	-38.23%
% of Gross Profit	89.69%	117.97%	169.77%
Depreciation & Amortization	$213.0K	$200.0K	$120.0K
YoY Change	77.5%	100.0%	9.09%
% of Gross Profit	1.46%	1.98%	1.64%
Operating Expenses	$34.50M	$33.55M	$34.57M
YoY Change	-0.2%	3.94%	-13.23%
Operating Profit	-$19.92M	-$23.44M	-$27.26M
YoY Change	-26.94%	-19.52%	-31.57%
Interest Expense	$20.00K	$73.00K	$270.0K
YoY Change	-92.59%	-81.28%	-73.27%
% of Operating Profit
Other Income/Expense, Net	-$7.420M	-$6.844M	-$170.0K
YoY Change	4264.71%	8455.0%	21.43%
Pretax Income	-$27.32M	-$30.21M	-$27.15M
YoY Change	0.61%	4.84%	-30.33%
Income Tax	$1.137M	$0.00	$3.370M
% Of Pretax Income
Net Earnings	-$28.45M	-$30.21M	-$30.53M
YoY Change	-6.81%	4.84%	-21.66%
Net Earnings / Revenue	-175.91%	-266.15%	-383.06%
Basic Earnings Per Share		-$1.35
Diluted Earnings Per Share	-$1.268M	-$1.350M	-$1.378M
COMMON SHARES
Basic Shares Outstanding	22.42M	22.38M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$89.14M	$106.2M	$102.0M
YoY Change	-12.62%	-11.2%	-30.64%
Cash & Equivalents	$44.36M	$55.34M	$52.86M
Short-Term Investments	$44.78M	$50.87M	$49.15M
Other Short-Term Assets	$8.702M	$7.339M	$4.600M
YoY Change	89.17%	33.44%	206.67%
Inventory	$4.832M	$3.808M	$1.964M
Prepaid Expenses
Receivables	$11.72M	$7.784M	$7.047M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$114.4M	$125.1M	$115.6M
YoY Change	-1.06%	-3.22%	-22.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.967M	$1.978M	$2.046M
YoY Change	-3.86%	14.67%	109.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$675.0K	$4.071M	$1.900M
YoY Change	-64.47%	-31.0%	-96.09%
Other Assets	$1.311M	$1.773M	$66.00K
YoY Change	1886.36%	491.0%	-75.0%
Total Long-Term Assets	$5.356M	$9.463M	$6.386M
YoY Change	-16.13%	-10.73%	-88.12%
TOTAL ASSETS
Total Short-Term Assets	$114.4M	$125.1M	$115.6M
Total Long-Term Assets	$5.356M	$9.463M	$6.386M
Total Assets	$119.7M	$134.6M	$122.0M
YoY Change	-1.85%	-3.79%	-39.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.786M	$4.060M	$3.271M
YoY Change	76.89%	-1.79%	-30.32%
Accrued Expenses	$14.35M	$14.61M	$17.50M
YoY Change	-17.98%	8.23%	18.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.38M	$19.81M	$21.44M
YoY Change	4.4%	12.53%	10.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$88.95M	$83.26M	$4.200M
YoY Change	2017.93%	4797.65%	61.54%
Total Long-Term Liabilities	$0.00	$83.26M	$4.200M
YoY Change	-100.0%	4797.65%	61.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.38M	$19.81M	$21.44M
Total Long-Term Liabilities	$0.00	$83.26M	$4.200M
Total Liabilities	$111.3M	$103.1M	$25.65M
YoY Change	334.05%	431.27%	16.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$467.3M	-$438.9M	-$356.5M
YoY Change	31.08%	34.63%	56.36%
Common Stock	$475.8M	$470.4M	$452.6M
YoY Change	5.12%		10.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.413M	$31.54M	$96.36M
YoY Change
Total Liabilities & Shareholders Equity	$119.7M	$134.6M	$122.0M
YoY Change	-1.85%	-3.79%	-39.72%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$28.45M	-$30.21M	-$30.53M
YoY Change	-6.81%	4.84%	-21.66%
Depreciation, Depletion And Amortization	$213.0K	$200.0K	$120.0K
YoY Change	77.5%	100.0%	9.09%
Cash From Operating Activities	-$20.07M	-$18.48M	-$21.25M
YoY Change	-5.55%	-26.33%	-18.27%
INVESTING ACTIVITIES
Capital Expenditures	-$202.0K	-$194.0K	-$180.0K
YoY Change	12.22%	-70.61%	-10.0%
Acquisitions
YoY Change
Other Investing Activities	$9.327M	$10.85M	$49.63M
YoY Change	-81.21%	-21.91%	422.97%
Cash From Investing Activities	$9.125M	$10.66M	$49.47M
YoY Change	-81.55%	-19.43%	431.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-32.00K	-168.0K	80.00K
YoY Change	-140.0%	-380.0%	-66.67%
NET CHANGE
Cash From Operating Activities	-20.07M	-18.48M	-21.25M
Cash From Investing Activities	9.125M	10.66M	49.47M
Cash From Financing Activities	-32.00K	-168.0K	80.00K
Net Change In Cash	-10.98M	-7.984M	28.30M
YoY Change	-138.79%	-32.28%	-271.93%
FREE CASH FLOW
Cash From Operating Activities	-$20.07M	-$18.48M	-$21.25M
Capital Expenditures	-$202.0K	-$194.0K	-$180.0K
Free Cash Flow	-$19.87M	-$18.28M	-$21.07M
YoY Change	-5.7%	-25.14%	-18.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22420325
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22404845
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22404845
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22167791
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22167791
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22400000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22200000
	urgn	Maximum Term For Commitment To Continue Employment Of Research And Development Jobs MaximumTermForCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs	P3Y
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55337000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52864000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	50872000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	49154000	USD
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1226000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1226000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7784000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7047000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	3808000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	1964000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6113000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3364000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	125140000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	115619000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1978000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2046000	USD
CY2021Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	USD
CY2020Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1418000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2158000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4071000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1893000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1773000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	66000	USD
CY2021Q3	us-gaap	Assets Assets	134603000	USD
CY2020Q4	us-gaap	Assets Assets	122005000	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11062000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10023000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6476000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9554000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2268000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1859000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	19806000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21436000	USD
CY2021Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	79927000	USD
CY2020Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	0	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	616000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1497000	USD
CY2021Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2717000	USD
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2717000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	103066000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	25650000	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	61000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	60000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	470341000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	452525000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-438869000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356501000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	271000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	31537000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	96355000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134603000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122005000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11351000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3461000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31868000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3833000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1244000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	309000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3568000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	357000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	10107000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	3152000	USD
	us-gaap	Gross Profit GrossProfit	28300000	USD
	us-gaap	Gross Profit GrossProfit	3476000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11923000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10211000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34560000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34905000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21624000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22065000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	66117000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68056000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23440000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29124000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72377000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-99485000	USD
CY2021Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	6828000	USD
CY2020Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	-0	USD
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	9948000	USD
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	-0	USD
CY2021Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	57000	USD
CY2020Q3	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	308000	USD
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	269000	USD
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	1527000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30211000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28816000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-82056000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-97958000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	312000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-30211000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-28816000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-97958000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-30211000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-28816000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-97958000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-41000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-268000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-267000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	216000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30252000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29084000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82635000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-97742000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.35
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.31
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.52
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22380598
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22058343
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22318589
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21657712
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	56271000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5515000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-41000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-30211000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	31537000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	142660000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	188000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6763000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-268000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-28816000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	120527000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	96355000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17756000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-267000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	31537000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	180302000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	691000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21499000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15777000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	216000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-97958000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	120527000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-97958000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	618000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	295000	USD
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8583000	USD
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-343000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-386000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17756000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21499000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	704000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1134000	USD
	urgn	Operating Lease Liability Noncash Adjustments OperatingLeaseLiabilityNoncashAdjustments	914000	USD
	urgn	Operating Lease Liability Noncash Adjustments OperatingLeaseLiabilityNoncashAdjustments	1157000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1844000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1346000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	737000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2810000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2749000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3261000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1573000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1032000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2506000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3078000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1080000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-595000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64822000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84644000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	51594000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	29687000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2463000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt		USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	44625000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	74503000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	550000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1043000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5056000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	43773000	USD
	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	72417000	USD
	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	651000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15853000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	127000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	55000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72351000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16449000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2473000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24422000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54090000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50211000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56563000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25789000	USD
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	-36000	USD
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	51000	USD
	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	7000	USD
	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	urgn	Non Cash Exercise Of Stock Options NonCashExerciseOfStockOptions	0	USD
	urgn	Non Cash Exercise Of Stock Options NonCashExerciseOfStockOptions	40000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p>
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biopharmaceutical company focused on building and commercializing novel solutions that treat specialty cancers and urologic diseases. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101</em> and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low grade-UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em> as filed with the Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 18, 2021.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. Intercompany balances and transactions have been eliminated during consolidation.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $</span>438.9 million and $356.5 million as of <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next <em style="font: inherit;">12</em> months. The Company anticipates that it will need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-438900000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356500000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p>
CY2021Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	110300000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4060000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3271000	USD
CY2021Q3	urgn	Accrued Sales Reserve AccruedSalesReserve	847000	USD
CY2020Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	382000	USD
CY2021Q3	urgn	Accrued Clinical Expense AccruedClinicalExpense	2504000	USD
CY2020Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1359000	USD
CY2021Q3	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1406000	USD
CY2020Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1356000	USD
CY2021Q3	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1638000	USD
CY2020Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2440000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	607000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1215000	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11062000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10023000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	345000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1719000	USD
	urgn	Other Finance Income Expense OtherFinanceIncomeExpense	-76000	USD
	urgn	Other Finance Income Expense OtherFinanceIncomeExpense	-192000	USD
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	269000	USD
	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	1527000	USD
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4106000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1051000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1275000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	913000	USD
CY2021Q3	urgn	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	5381000	USD
CY2020Q4	urgn	Inventory Current And Noncurrent Net Of Reserves InventoryCurrentAndNoncurrentNetOfReserves	1964000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	90863000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	90867000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	100000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	11900000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	13	pure
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	86797000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	88898000	USD
CY2021Q3	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4070000	USD
CY2020Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	1893000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	90867000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	90791000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3991000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3441000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2013000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1395000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1978000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2046000	USD
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2021Q2	urgn	Prepaid Forward Obligation PrepaidForwardObligation	75000000	USD
	urgn	Capitalized Closing Costs On Prepaid Forward Obligation CapitalizedClosingCostsOnPrepaidForwardObligation	2583000	USD
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	9948000	USD
	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	2438000	USD
CY2021Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	79927000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	259000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	424000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	786000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1282000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	56000	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	56000	USD
	us-gaap	Sublease Income SubleaseIncome	168000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1418000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2158000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	616000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1497000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1133000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1202000	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
	us-gaap	Sublease Income SubleaseIncome	168000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	15000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	28000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	51000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	114000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	218000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	396000	USD
	us-gaap	Lease Cost LeaseCost	669000	USD
	us-gaap	Lease Cost LeaseCost	1228000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2734000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	135000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M4D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0551	pure
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	59000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	243000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	251000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	49000	USD
CY2021Q3	urgn	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	0	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	602000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	56000	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	56000	USD
	us-gaap	Sublease Income SubleaseIncome	168000	USD
	us-gaap	Sublease Income SubleaseIncome	168000	USD
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22400000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22200000
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3587774
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1362156
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5515000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6763000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17756000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21499000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	22900000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M3D
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2021Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	700000	USD
CY2020Q1	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	6600000	USD
	urgn	Maximum Percentage Of Commitment To Continue Employment Of Research And Development Jobs MaximumPercentageOfCommitmentToContinueEmploymentOfResearchAndDevelopmentJobs	0.75	pure

Files In Submission

Name	View Source	Status
0001437749-21-026620-index-headers.html	Edgar Link	pending
0001437749-21-026620-index.html	Edgar Link	pending
0001437749-21-026620.txt	Edgar Link	pending
0001437749-21-026620-xbrl.zip	Edgar Link	pending
ex_283901.htm	Edgar Link	pending
ex_283902.htm	Edgar Link	pending
ex_283903.htm	Edgar Link	pending
ex_283904.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20210930.xsd	Edgar Link	pending
urgn-20210930_cal.xml	Edgar Link	unprocessable
urgn-20210930_def.xml	Edgar Link	unprocessable
urgn-20210930_lab.xml	Edgar Link	unprocessable
urgn-20210930_pre.xml	Edgar Link	unprocessable
urgn20210930_10q.htm	Edgar Link	pending
urgn20210930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2021 Q4 Form 10-Q Financial Statement

#000143774921026620 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2021 Q4 Form 10-Q Financial Statement

#000143774921026620 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn